Key highlights
7* tests contributing to saving costs and protecting life
USD 1.4bn serviceable market with 5-10% annual growth
Entered partnerships with 5 major global IVD companies
Scalable, lean and flexible commercial model
Delivered ~23% annual revenue growth 2020-25
2 ‘blockbuster’ tests in market and product development
Industry leading team and knowhow
Team with proven track-record and industry expertise from market leading IVD companies
Gentian’s strategy for long-term growth and value creation
Gentian Diagnostic’s purpose is to deliver efficient diagnostics for better treatment decisions.
The growing diagnostics market puts increasing pressure on clinical laboratory efficiency. However, many of the existing, clinically relevant biomarkers are available only on slow and inefficient platforms. Gentian’s solution is to utilize PETIA (particle-enhanced turbidimetric immunoassays), based on proprietary nanoparticle technology and knowhow, to convert existing biomarkers to the most efficient automated, high-throughput analysers.
Gentian’s portfolio of high-impact diagnostic tests targets several large and growing disease areas such as infections and inflammation, kidney disease and heart failure. The company has four established products – Cystatin C, fCAL® turbo, Canine CRP (cCRP) and fPELA® turbo – that contributed to 23% annual revenue growth in 2020-2025. In addition, GCAL has been launched and is in market development. The company also has undisclosed projects in exploration and optimisation phases.
The company’s roadmap for long-term growth and value creation is founded on six strategic pillars:
- Grow annual revenue from the company’s established products by expanding market access through additional commercial partners and regulatory approvals.
- Prove clinical relevance of GCAL.
- Bring a steady stream of new high-impact diagnostic tests to market.
- Secure one new contract with a global commercial partner every year, building on already established partnerships with major diagnostic companies across products.
- Grow gross margin from ~50% to 60%+ through economies of scale.
- Deliver long-term EBITDA margins of 40% through operational leverage and cost discipline, assuming that current investment levels are maintained.
*5 established tests, 1 in market development and further 1 in product development.
Gentian Diagnostics ASA - Prospectus
